CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Stopped will not resume. company choosing not to continue with drug. one participant now off study.

Conditions

• Ovarian Cancer
• Resistant BRCA Wild-Type Ovarian Cancer

Interventions

• DRUG: Cohort 1: Dose Escalation
• DRUG: Cohort 2: Dose Escalation

Sponsor

University of Alabama at Birmingham